Pembrolizumab for patients with advanced melanoma.
Talha Khan
TK
Burki
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D017326:Clinical Trials, Phase III as Topic; D006801:Humans; D008545:Melanoma / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D009367:Neoplasm Staging; D061026:Programmed Cell Death 1 Receptor / Q000235:genetics; D016032:Randomized Controlled Trials as Topic
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; C105992:PDCD1 protein, human; D061026:Programmed Cell Death 1 Receptor; C582435:pembrolizumab